{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:06Z","timestamp":1787840406803,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Neuromyelitis optica (NMO) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features; multiple therapeutic agents have been used with different results. Recent evidence points to B-cell-mediated humoral immunity in the pathogenesis of NMO. Rituximab targets the CD20 antigen on B-cells. Treatment leads to profound B-cell depletion, principally over an antibody-dependent cell cytotoxicity mechanism. The aim of our study was to review clinical trials to elucidate the impact of rituximab on the relapse rate, Expanded Disability Status Scale (EDSS), and progression of disability in NMO. We performed a comprehensive review of all studies that evaluated clinical and paraclinical effects of rituximab on NMO. MEDLINE-PubMed, Web of Sciences, EMBASE, and Cochrane databases up to June 2016 included in our searches. In addition, reference lists from articles identified by search as well as a key review article to identify additional articles included in the study. Rituximab targets the CD20 antigen on B-cells and decreases attack frequency and severity in patients with NMO; however, it does not remove attacks, even when modifying treatment to achieve B-cell depletion. Most of the investigations revealed that EDSS significantly in all patients with rituximab treatment will be decreased after treatment with rituximab. No new or enlarged lesions or pathological gadolinium enhancement was observed in serial brain and spinal cord magnetic resonance imaging, except for those observed concomitantly with clinical relapses and the median length of spinal cord lesions was significantly reduced after therapy. Rituximab targets the CD20 antigen and decreases attack frequency and severity in patients with NMO.<\/jats:p>","DOI":"10.4103\/1735-1995.200275","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T02:20:56Z","timestamp":1487211656000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence"],"prefix":"10.4103","volume":"22","author":[{"given":"Masoud","family":"Etemadifar","sequence":"first","affiliation":[{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Salari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mirmosayyeb","sequence":"additional","affiliation":[{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Medical Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Serati","sequence":"additional","affiliation":[{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roham","family":"Nikkhah","sequence":"additional","affiliation":[{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mozhde","family":"Askari","sequence":"additional","affiliation":[{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"},{"name":"Medical Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Fayyazi","sequence":"additional","affiliation":[{"name":"Isfahan Research Committee of Multiple Sclerosis, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2009.08.045","article-title":"Neuromyelitis optica: Effect of gender","volume":"286","author":"Wingerchuk","year":"2009","journal-title":"J Neurol Sci"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","article-title":"Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?","volume":"2","author":"Zamvil","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R6-20250827","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00281-014-0424-x","article-title":"B cells in MS and NMO: Pathogenesis and therapy","volume":"36","author":"Krumbholz","year":"2014","journal-title":"Semin Immunopathol"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.4049\/jimmunol.164.5.2782","article-title":"Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients","volume":"164","author":"Colombo","year":"2000","journal-title":"J Immunol"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"R12-20250827","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s10072-014-2039-3","article-title":"When do we judge IVIg for myasthenia gravis ineffective?","volume":"36","author":"Takizawa","year":"2015","journal-title":"Neurol Sci"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"R14-20250827","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.brainres.2015.06.053","article-title":"Regenerative cellular therapies for neurologic diseases","volume":"1638","author":"Levy","year":"2016","journal-title":"Brain Res"},{"issue":"Suppl 1","key":"R15-20250827","first-page":"S24","article-title":"Differential diagnosis and treatment of impaired bladder emptying","volume":"6","author":"Yoshimura","year":"2004","journal-title":"Rev Urol"},{"key":"R16-20250827","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2015.05.007","article-title":"Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica","volume":"283","author":"Akaishi","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jneuroim.2014.11.011","article-title":"Association of circulating follicular helper T cells with disease course of NMO spectrum disorders","volume":"278","author":"Li","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R19-20250827","first-page":"1294","article-title":"B-cell markers predict response of rituximab in systemic lupus erythematosus","volume":"3","author":"Christoph","year":"2011","journal-title":"Immunotherapy"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13760-013-0178-6","article-title":"Treatment of NMO relapse in the elderly: Rituximab when plasma exchange fails?","volume":"113","author":"Bourre","year":"2013","journal-title":"Acta Neurol Belg"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nrl.2013.12.022","article-title":"Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica","volume":"30","author":"de Andr\u00e9s","year":"2015","journal-title":"Neurologia"},{"key":"R22-20250827","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/NXI.0000000000000046","article-title":"Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children","volume":"1","author":"Longoni","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R23-20250827","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"R24-20250827","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci"},{"key":"R25-20250827","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"R26-20250827","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"key":"R27-20250827","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"R28-20250827","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: Efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J Neurol"},{"key":"R29-20250827","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.nrl.2014.09.001","article-title":"Clinical evaluation of rituximab treatment for neuromyelitis optica","volume":"30","author":"Fern\u00e1ndez-Meg\u00eda","year":"2015","journal-title":"Neurologia"},{"key":"R30-20250827","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"R31-20250827","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"R32-20250827","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0883073814553974","article-title":"Prolonged remission in neuromyelitis optica following cessation of rituximab treatment","volume":"30","author":"Weinfurtner","year":"2015","journal-title":"J Child Neurol"},{"key":"R33-20250827","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol Sci"},{"key":"R34-20250827","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2014.02.007","article-title":"Rituximab use in pediatric central demyelinating disease","volume":"51","author":"Beres","year":"2014","journal-title":"Pediatr Neurol"},{"key":"R35-20250827","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: Long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:22:01Z","timestamp":1787836921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.200275","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-08-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-11-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}